Collaboration agreement with Korean research institute

PHI announces the signing of a collaboration agree­ment with Korea Research Institute of Bioscience and Biotechnology (KRIBB). KRIBB is Korea’s only governmental research institute dedicated to research across a broad span of biotechnology research areas.

“We are of course pleased to have estab­lished a col­labora­tion with an opinion leader like KRIBB. This is very helpful to our work to achieve scientific accept­ance and thereby strengthen our products in the market. KRIBB is a govern­ment research institute with major national influence and is inter­nationally known for its research, particularly the research we address with our products – tumor growth and cell pro­lifera­tion. KRIBB is strategically located in Daejeon which is the center for Korea’s big push to become a leader of life science research”, says Peter Egelberg, CEO of PHI.

Research scientist Sung-Kyun Ko, KRIBB

In accordance with the collaboration agree­ment, KRIBB will borrow a HoloMonitor M4 over 12 months. The KRIBB research team will use the Holo­Monitor M4 to study the effect various treat­ments have on cell motility. The pre­liminary results that have been obtained during an evaluation period are very en­coura­ging. The purpose of col­labora­tion is to expand on these preliminary results for scientific pub­lication. KRIBB will also serve as a reference customer for the Daejeon region.

“The HoloMonitor M4 allow us to rapidly measure how cell motility is affected by various treatments, without removing the cells from our incubator”, says research scientist Sung-Kyun Ko at KRIBB.

FOR MORE INFORMATION ABOUT KRIBB AND THE KOREAN MARKET:

www.kribb.re.kr
www.mva.org/south-korea-heads-bio-top-7
en.wikipedia.org/wiki/Daejeon